Bayer's €2 Billion Hybrid Bond: Financing the Glyphosate Endgame Without Diluting Shareholders
Published on 09/24/2026 at 08:40 | Editorial boerse-global.de
Bayer has turned to the hybrid bond market to buy itself room on a legal problem that has shadowed its balance sheet for years. Late Wednesday, after the close of trading in Frankfurt, the Leverkusen-based agricultural and pharmaceutical group placed two tranches of subordinated notes worth a combined €2 billion. The paper carries a 30-year maturity, and demand ran hot — both tranches were multiple times oversubscribed.
The structure matters as much as the size. Hybrids sit between debt and equity, and rating agencies typically count them as 50% economic equity. That lets Bayer thicken its capital buffers without issuing new ordinary shares, sparing existing holders the dilution a conventional rights issue would bring. Management has been explicit that a dilutive capital increase is off the table for now.
A €6.55 Billion Hybrid Stack
With the new notes on the books, Bayer's total outstanding hybrid volume climbs to €6.55 billion — half of which the ratings agencies recognize as equity. The three-decade tenor also hands the company unusual flexibility on interest and repayment scheduling, a meaningful advantage when the direction of rates remains unsettled.
The pricing, however, is not cheap. The tranche carrying a six-year non-call period pays a 5.75% coupon, while the tranche with a nine-year lock-in carries 6.25%. Those obligations will weigh on the financial result for years and crimp future investment budgets.
Should investors sell immediately? Or is it worth buying Bayer?
Apollo, Dollar Bonds and a €375 Million Divestment
Wednesday's placement slots into a broader financing push assembled over recent months. Bayer has already raised €3 billion in equity from Apollo, which took a stake in the company's LARC business, and has issued conventional bonds totaling $5 billion. Alongside those moves, the group is shedding non-core assets — among them the sale of oncology drug Stivarga to Grünenthal, a deal worth up to €375 million.
Proceeds from the hybrid issue are earmarked for general corporate purposes, and they strengthen the base for the refinancings still ahead.
The $7.25 Billion Question
Everything ultimately circles back to one number: the $7.25 billion glyphosate settlement agreed in February, equivalent at the time to roughly €6.3 billion. A preliminary approval is in hand, but the final judicial sign-off has yet to arrive. Until that ruling is enforceable, an $8 billion credit facility — set up to backstop both the settlement and upcoming bond maturities — sits on the balance sheet as a potential block, to be unwound step by step through bonds and equity-like instruments.
For investors, the central issue is whether the liquidity being assembled is deep enough to close out the US litigation without structurally overburdening the balance sheet. If the chain of Apollo money, divestments and bond issuance holds until the court rules, Bayer can retire its largest legal overhang without selling a single new share. If the judge rejects the settlement at the final stage, the company faces a different landscape: the $8 billion facility would have to be serviced under altered terms, individual claims could resurface, and rating agencies would likely tighten the screws — putting a conventional capital increase abruptly back on the table.
What the Market Is Pricing
Shareholders have so far backed the strategy. The stock closed Wednesday at €49.51, with pre-market indications Thursday pointing to a slight decline to €49.33. Since the start of the year, the shares have gained between 33% and 34%. The 50-day moving average sits at €48.42, a level that has served as a rough floor for the recovery narrative.
Bayer at a turning point? This analysis reveals what investors need to know now.
As long as the preliminary glyphosate agreement holds and the price stays above that line, the repair story stays intact — investors rewarding the gradual hedging of liabilities and the preservation of the shareholder base through rating-relevant hybrid capital. A negative final ruling would reopen the valuation discount the market has already written down and throw the costly refinancing strategy into disarray.
The next decisive catalyst is therefore the pending final court decision on the $7.25 billion settlement. Beyond it, attention could shift back to operations, where Bayer aims to shore up margins through efficiency programs — including the joint deployment of specialized software with partners to speed up administrative processes.
Ad
Bayer Stock: New Analysis - 24 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
